{"symbol":"REGN","fiscalQuarter":"Q3-2012","reportDate":"2012-10-24","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2012","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 6.34%","keyNumbers":[{"metric":"EPS","actual":"$1.89","expected":"N/A","surprise":"+104.32%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["We are pleased with our performance this quarter.","Our focus remains on advancing our pipeline."],"summary":"Management expressed satisfaction with the quarterly results, highlighting their commitment to pipeline advancements. They did not provide specific guidance for future performance."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong earnings per share beat expectations significantly, which contributed to a positive stock reaction, rising by 6.34%. The lack of revenue data leaves some uncertainty, but the management's confidence in their pipeline suggests potential for future growth. Investors may view this as a positive sign for the company's ongoing projects and overall health.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2012 earnings: EPS beat by 104.32%. Stock up 6.34%. Full breakdown."}}